Alzheimer’s disease has a devastating impact on patients, their loved ones and the caregivers who help them navigate their daily lives. It’s a particularly cruel disease – one that is especially difficult to treat, slow or prevent.
The puzzle of Alzheimer’s is one that biopharmaceutical research companies are working hard to solve – studying the diseases’ complexity and developing new, evolved treatment options.
To take a closer look at the science and advancements driving Alzheimer’s research today, PhRMA will host a live webcast at 1:30 p.m. on July 15 at www.phrma.org/alz15. Discussion will focus on the findings of PhRMA’s new report, “Researching Alzheimer’s Medicines: From Setbacks to Stepping Stones,” which explores progress in Alzheimer’s research and development, including the 59 current medicines in development for Alzheimer’s and other dementias.
The expert panel will feature executive leaders who will share their thoughts on the promise of Alzheimer’s research and care, including:
- William W. Chin, M.D., executive vice president, PhRMA
- Robert J. Egge, chief public policy officer, Alzheimer’s Association
- Sue Peschin, MHS, president and chief executive officer, Alliance for Aging Research
- George A. Scangos, Ph.D., chief executive officer, Biogen
Be sure to tune in on Wednesday, July 15 at 1:30pm to watch the live webcast at www.phrma.org/alz15 and join in the conversation by tweeting your questions to @PhRMA with the hashtag #Alz15.
Tina Stow Tina Stow previously served as Vice President of Communications at PhRMA. Prior to joining PhRMA in 2014, she spent more than a dozen years in corporate and agency communications and public affairs roles. A D.C. transplant via North Carolina and Georgia, Tina likes to travel, make the rounds to D.C.’s new restaurants, dote on her rescue labradoodle (Chloe), and complain about winter.